Cover Image
市場調查報告書

纖維肌痛 : 開發平台分析

Fibromyalgia - Pipeline Review, H1 2017

出版商 Global Markets Direct 商品編碼 232816
出版日期 內容資訊 英文 62 Pages
訂單完成後即時交付
價格
Back to Top
纖維肌痛 : 開發平台分析 Fibromyalgia - Pipeline Review, H1 2017
出版日期: 2017年02月28日 內容資訊: 英文 62 Pages
簡介

纖維肌痛會造成肌肉骨骼系統大範圍疼痛。主要的症狀有倦怠感,頭痛,下腹部疼痛等。這個疾病的原因有遺傳要素,類風濕性關節炎,狼瘡等。

本報告提供纖維肌痛治療藥的開發情形的相關調查,提供您開發中產品概要,臨床實驗的各階段產品概要,主要企業簡介,藥物簡介,開發中產品的最新趨勢等資訊。

簡介

  • 調查範圍

纖維肌痛概要

治療藥的開發

  • 開發中產品的概要
  • 開發中產品比較分析

纖維肌痛:企業開發中的治療藥

大學/機關研究中的治療藥

纖維肌痛:開發中產品概況

  • 後期階段的產品
  • 臨床階段的產品
  • 初期階段的產品

纖維肌痛:企業開發中的產品

大學/機關研究中的產品

纖維肌痛治療藥的開發企業

  • 第一三共
  • Intellipharmaceutics International Inc.
  • Merck & Co., Inc.
  • SWITCH Biotech LLC
  • Tonix Pharmaceuticals Holding Corp.
  • Zynerba Pharmaceuticals, Inc.

纖維肌痛:治療藥的評估

  • 單劑產品
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

  • mirogabalin besylate
  • mirtazapine ODT
  • naltrexone hydrochloride
  • Peptide to Block Voltage-Dependent N-Type Calcium Channel for Cancer Pain and Fibromyalgia
  • pregabalin XR
  • Small Molecules for Fibromyalgia
  • SWT-06101
  • TD-9855
  • TNX-102
  • ZYN-001

纖維肌痛:最近的開發平台趨勢

纖維肌痛:暫停中的計劃

纖維肌痛:開發中止的產品

纖維肌痛:產品開發的里程碑

  • 主要消息和新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8950IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Fibromyalgia - Pipeline Review, H1 2017, provides an overview of the Fibromyalgia (Central Nervous System) pipeline landscape.

Fibromyalgia is a disorder characterized by widespread musculoskeletal pain accompanied by fatigue, sleep, memory and mood issues. Symptoms include fatigue, depression, headaches, and pain or cramping in the lower abdomen. The predisposing factors include family history, rheumatoid arthritis or lupus. Treatment includes pain relievers, antidepressants and anti-seizure drugs.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Fibromyalgia - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Fibromyalgia (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Fibromyalgia (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Fibromyalgia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 3, 6, 1 and 4 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Fibromyalgia (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Fibromyalgia (Central Nervous System).
  • The pipeline guide reviews pipeline therapeutics for Fibromyalgia (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Fibromyalgia (Central Nervous System) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Fibromyalgia (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Fibromyalgia (Central Nervous System)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Fibromyalgia (Central Nervous System).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Fibromyalgia (Central Nervous System) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Fibromyalgia - Overview
  • Fibromyalgia - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Pipeline by Universities/Institutes
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Fibromyalgia - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Fibromyalgia - Companies Involved in Therapeutics Development
    • Astellas Pharma Inc
    • Daiichi Sankyo Company Ltd
    • Immune Therapeutics Inc
    • Innovative Med Concepts LLC
    • Jiangsu Hengrui Medicine Co Ltd
    • KPI Therapeutics Inc
    • Merck & Co Inc
    • Pfizer Inc
    • SWITCH Biotech LLC
    • Theravance Biopharma Inc
    • Vitality Biopharma Inc
    • Zynerba Pharmaceuticals Inc
  • Fibromyalgia - Drug Profiles
    • (celecoxib + famciclovir) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AS-1069562 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ASP-0819 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ASP-8062 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • mirogabalin besylate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • mirtazapine ODT - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • naltrexone hydrochloride - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Peptide to Block Voltage-Dependent N-Type Calcium Channel for Central Nervous System - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • pregabalin CR - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • pregabalin SR - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SWT-06101 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • TD-9855 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • U-2902 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • VB-210 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ZYN-001 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Fibromyalgia - Dormant Projects
  • Fibromyalgia - Discontinued Products
  • Fibromyalgia - Product Development Milestones
    • Featured News & Press Releases
      • Oct 17, 2016: Zynerba Provides Clinical Update for Lead Development Candidate ZYN001
      • Jan 28, 2016: Innovative Med Concepts Announces Receipt of FDA Fast Track Designation for IMC-1, a Novel Treatment for Fibromyalgia
      • Feb 04, 2015: Daiichi Sankyo Announces First Patients in Large-scale, Multi-national Phase 3 Clinical Programs for Mirogabalin
      • Nov 18, 2014: Novel Fibromyalgia Treatment Shows Promise In Study
      • Apr 30, 2014: Theravance Announces Positive Results From a Phase 2 Study of TD-9855 in Patients With Fibromyalgia
      • Dec 04, 2012: Theravance Initiates Phase II Study With TD-9855 For Treatment Of Fibromyalgia
      • Nov 27, 2012: Intellipharmaceutics Announces Results Of Initial Phase I Clinical Trial Of Controlled-release Pregabalin
      • Nov 19, 2012: Pfizer Reports Top-line Results Of Phase III Study Evaluating Pregabalin Controlled-release As Treatment For Patients With Fibromyalgia
      • Jul 23, 2012: Pfizer Reports Top-Line Results Of EU Post-Authorization Safety And Efficacy Study Of Lyrica's Discontinuation Effects In Patients With Generalized Anxiety Disorder
      • Feb 02, 2009: UCB Announces Top-Line Outcomes For Proof-Of-Concept Studies
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Fibromyalgia, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017
  • Products under Development by Companies, H1 2017
  • Products under Development by Universities/Institutes, H1 2017
  • Number of Products by Stage and Target, H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017
  • Number of Products by Stage and Route of Administration, H1 2017
  • Number of Products by Stage and Molecule Type, H1 2017
  • Fibromyalgia - Pipeline by Astellas Pharma Inc, H1 2017
  • Fibromyalgia - Pipeline by Daiichi Sankyo Company Ltd, H1 2017
  • Fibromyalgia - Pipeline by Immune Therapeutics Inc, H1 2017
  • Fibromyalgia - Pipeline by Innovative Med Concepts LLC, H1 2017
  • Fibromyalgia - Pipeline by Jiangsu Hengrui Medicine Co Ltd, H1 2017
  • Fibromyalgia - Pipeline by KPI Therapeutics Inc, H1 2017
  • Fibromyalgia - Pipeline by Merck & Co Inc, H1 2017
  • Fibromyalgia - Pipeline by Pfizer Inc, H1 2017
  • Fibromyalgia - Pipeline by SWITCH Biotech LLC, H1 2017
  • Fibromyalgia - Pipeline by Theravance Biopharma Inc, H1 2017
  • Fibromyalgia - Pipeline by Vitality Biopharma Inc, H1 2017
  • Fibromyalgia - Pipeline by Zynerba Pharmaceuticals Inc, H1 2017
  • Fibromyalgia - Dormant Projects, H1 2017
  • Fibromyalgia - Dormant Projects, H1 2017 (Contd..1), H1 2017
  • Fibromyalgia - Discontinued Products, H1 2017

List of Figures

  • Number of Products under Development for Fibromyalgia, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products by Top 10 Targets, H1 2017
  • Number of Products by Stage and Top 10 Targets, H1 2017
  • Number of Products by Top 10 Mechanism of Actions, H1 2017
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
  • Number of Products by Routes of Administration, H1 2017
  • Number of Products by Stage and Routes of Administration, H1 2017
  • Number of Products by Molecule Types, H1 2017
  • Number of Products by Stage and Molecule Types, H1 2017
Back to Top